Izotropic Corporation(“
Izotropic” or the “Company”)(CSE:IZO)(CNSX:IZO.CN)(OTC:IZOZF) (FSE:1R3)a Company commercializing “Izoview”, a true 3D, dedicated Breast Computed Tomography (CT) imaging technology for the diagnostic identification of breast cancers, provides updates on the following:
- Izoview, 5thgeneration, enhanced product design for performance improvements, added usability, increasing competitive advantages and target market
- Clinical study and regulatory pathway for regulatory authorization and market preparation process
- Product and clinical development milestones for the initial Izoview device
Izotropic announced today it has completed a comprehensive review of its R&D strategy to yield a differentiated offering for the Company’s priority markets, while positioning the business for continual innovation and disruptive breakthroughs. A combination of Covid-19 related delays and discussions with key suppliers of primary components
Vancouver, British Columbia (Newsfile Corp. - June 3, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") a Company commercializing "Izoview", a true 3D
for the groundbreaking ADA FDI 2021 World Dental Congress – Special Edition, which will be broadcast live, on demand and worldwide as a virtual event across 26-29 September this year.
The event, themed Educating for Dental Excellence, will be the first of its kind to be held virtually. The opportunities presented by this format are many, offering a 60-day access period to replay sessions after they have been broadcast during the four days of the event, an Exhibition Showcase to allow delegates, exhibitors and sponsors to interact through video meeting features, and a programme delivering more than 200 scientific sessions, both live and pre-recorded, during the course of the event. Abstract submissions for E-Posters and Free Communications (short oral presentations) were finalised last month.